WWSNC NutritionPractitioner-guided wellness
← All ingredient guides A–Z

Evidence and label comparisons · WSNC nutrition education

Inositol Supplements: Tablet, Powder and Evidence Limitations

Inositol tablets and powder have different labeled portions. Compare the declared amount and identified form before applying findings from myo-inositol or D-chiro-inositol research; do not assume every inositol product has a studied fertility ratio.

Compare the exact preparation and labeled serving

The checked manufacturer panels declare 375 mg per Inositol tablet and 700 mg per quarter-teaspoon Inositol Powder portion. Those amounts do not establish a myo-to-D-chiro ratio or equivalence to gram-level protocols used in particular studies.

The amounts below reproduce the inspected manufacturer online panel. They describe labeled servings, not an individualized regimen. Confirm your selected package and review the full ingredient list and dietary attributes on the product page.

Declared manufacturer amounts checked October 14, 2026; compare the exact selected package
ProductDeclared serving factsImportant distinction
InositolView product →Declared serving factsEach Serving Size (1 Tablet) contains: Inositol 375 mg.Important distinctionRead the complete Inositol ingredient list and current package. The serving facts describe this formula; a shared ingredient does not make it equivalent to another product.
Inositol PowderView product →Declared serving factsEach Serving Size (1/4 Teaspoon) contains: Total Carbohydrate <1 g, Inositol 700 mg.Important distinctionRead the complete Inositol Powder ingredient list and current package. The serving facts describe this formula; a shared ingredient does not make it equivalent to another product.

References: WSNC Inositol recorded label details ↗ · WSNC Inositol Powder recorded label details ↗ · Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome ↗

What the ingredient evidence can establish

The 2023 international PCOS guideline describes possible metabolic effects but limited clinical benefits for outcomes such as ovulation, hirsutism and weight. It does not recommend a specific inositol type, dose or combination because the evidence is insufficient.

For infertility associated with PCOS, the guideline treats inositol as experimental because benefits and risks remain uncertain. An ingredient comparison cannot replace diagnosis, fertility care or prescribed metabolic treatment.

References: Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome ↗

Review suitability, medicines and the whole formula

Tell your clinician about inositol use, especially during fertility treatment, pregnancy planning or glucose management. Do not alter metformin or other prescribed treatment based on a supplement's description. Digestive tolerance and the complete daily routine also matter.

Clarify the intended outcome, exact form and how any benefit will be assessed. Use the manufacturer package directions while discussing suitability; a study amount is not a new WSNC dosing instruction.

References: WSNC Inositol recorded label details ↗ · WSNC Inositol Powder recorded label details ↗ · Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome ↗

Prepare a focused practitioner conversation

Bring the selected label, your reason for considering inositol, and a list of medicines and other supplements. Compare the intended outcome with the specific preparation studied, and agree how suitability and any benefit will be assessed.

Manufacturer suggested-use text checked for these products: Inositol: One tablet per meal, or as directed. Inositol Powder: One quarter teaspoon per day, or as directed. Warning: Keep out of reach of children.

These are separate product instructions, not one combined supplement schedule. Keep the current package directions with your practitioner plan; ingredient research does not override manufacturer labeling.

References: WSNC Inositol recorded label details ↗ · WSNC Inositol Powder recorded label details ↗ · Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome ↗

Common questions

How should I compare inositol supplement labels?

The checked manufacturer panels declare 375 mg per Inositol tablet and 700 mg per quarter-teaspoon Inositol Powder portion. Those amounts do not establish a myo-to-D-chiro ratio or equivalence to gram-level protocols used in particular studies.

Does ingredient research prove the complete formula works?

For infertility associated with PCOS, the guideline treats inositol as experimental because benefits and risks remain uncertain. An ingredient comparison cannot replace diagnosis, fertility care or prescribed metabolic treatment.

What should I discuss before considering inositol?

Tell your clinician about inositol use, especially during fertility treatment, pregnancy planning or glucose management. Do not alter metformin or other prescribed treatment based on a supplement's description. Digestive tolerance and the complete daily routine also matter.

Evidence and product label sources

WSNC label links below present recorded Standard Process product information on our site. Noncommercial references explain ingredients, evidence limits and safety; they do not verify every formula amount or establish a treatment outcome for a finished product or protocol. The referenced organizations do not endorse this store.

Manufacturer nutrition-panel amounts shown here were checked October 14, 2026. Confirm the current packaging, directions and dietary information before use. Your healthcare practitioner can help assess individual suitability.

How we research products → · Prepare a practitioner conversation →